﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 10:41:19 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer</title><link>https://news.cision.com/photocure/r/photocure-and-artera-to-partner-on-digital-pathology-ai-test-evaluation-for-bladder-cancer,c4359309</link><guid isPermaLink="false">cision5379365</guid><description><![CDATA[Press Release – Oslo, Norway, June 8, 2026: Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses Photocure’s blue light cystoscopy (BLC[®]) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.
As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. Photocure, already recognized]]></description><pubDate>Mon, 08 Jun 2026 16:08:49 GMT</pubDate></item><item><title>Recipharm and Fusix Biotech advance novel oncolytic virus platform</title><link>https://news.cision.com/recipharm-ab/r/recipharm-and-fusix-biotech-advance-novel-oncolytic-virus-platform,c4359079</link><guid isPermaLink="false">cision5379095</guid><description><![CDATA[· Collaboration to advance novel oncolytic virus-based cancer immunotherapies
  · Recipharm to support development and GMP manufacturing of Fusix Biotech’s FUSE102 programme and future pipeline candidates
  · Partnership reinforces Recipharm’s expertise in oncology biologics and viral-based therapies
Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced a strategic collaboration with Fusix Biotech to support the development and manufacturing of next-generation cancer immunotherapies based on innovative oncolytic virus technology.

Fusix]]></description><pubDate>Mon, 08 Jun 2026 09:51:00 GMT</pubDate></item><item><title>Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to China</title><link>https://news.cision.com/moberg-pharma/r/moberg-pharma-and-karo-healthcare-expand-collaboration-for-mob-015-terclara-to-china,c4358816</link><guid isPermaLink="false">cision5378800</guid><description><![CDATA[STOCKHOLM, June 8, 2026. Moberg Pharma AB (publ) has entered into a license agreement with Karo Healthcare AB regarding the commercialization of the nail fungus drug MOB-015 (Terclara[®]) in China through the rapidly growing cross-border e-commerce channel. The product is intended to be launched under the leading global antifungal brand Lamisil[®].
The agreement represents a further expansion of the strategic partnership initiated in November 2025, when Karo Healthcare obtained the rights to market, distribute and sell MOB-015 in 19 European markets with a combined population of]]></description><pubDate>Mon, 08 Jun 2026 06:00:00 GMT</pubDate></item><item><title>Klaria Annual Report 2025</title><link>https://news.cision.com/klaria-pharma-holding-ab/r/klaria-annual-report-2025,c4358669</link><guid isPermaLink="false">cision5378555</guid><description><![CDATA[Klaria Annual Report 1 January- 31 December 2025
The year in brief

- Net sales amounted to 9.0 MSEK (2.2 MSEK)

- Other operating income amounted to 0.0 MSEK (0.1 MSEK)

- R&D costs amounted to 28.3 MSEK (22.1 MSEK)

- Profit/loss after tax amounted to -47.1 MSEK (-47.8 MSEK)

- Earnings per share amounted to -0.25 SEK (-0.38 SEK)

- Cash flow from operations amounted to -34.2 MSEK (-11.9 MSEK)

- Shareholder’s equity as of December 31, 2025 amounted to -12.0 MSEK (3.3 MSEK)

- Cash and cash equivalents as of December 31, 2025 amounted to 0.3 MSEK (0.6 MSEK)]]></description><pubDate>Fri, 05 Jun 2026 20:48:26 GMT</pubDate></item><item><title>Klaria receives 25 MSEK in loan financing with the possibility of an additional 15 MSEK</title><link>https://news.cision.com/klaria-pharma-holding-ab/r/klaria-receives-25-msek-in-loan-financing-with-the-possibility-of-an-additional-15-msek,c4358632</link><guid isPermaLink="false">cision5378546</guid><description><![CDATA[Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that Klaria has entered into an agreement for a bridge loan of 25 MSEK from a Swedish finance company. The agreement also includes an option for the Company to borrow an additional 15 MSEK if necessary, which means that the total possible financing framework amounts to 40 MSEK.
The purpose of the bridge loan is to strengthen Klaria's financial flexibility during the ongoing process that the Company is conducting together with BDO London to access all available markets around the world.  Klaria would also like to highlight]]></description><pubDate>Fri, 05 Jun 2026 18:13:51 GMT</pubDate></item><item><title>Photocure ASA - Notice of the Annual General Meeting 26 June 2026</title><link>https://news.cision.com/photocure/r/photocure-asa---notice-of-the-annual-general-meeting-26-june-2026,c4358534</link><guid isPermaLink="false">cision5378415</guid><description><![CDATA[Oslo, Norway, 5 June 2026: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 26 June 2026 at 17:00 hours (CEST), virtual through the general meeting portal administered by Euronext Securities Oslo (the "Euronext Securities Portal").
The general meeting will be webcasted live and a link will be available on the company's website in due time in advance of the general meeting. It will not be possible to attend in person. Shareholders may also vote in advance or submit a proxy with voting instructions.

The notice convening the general meeting,]]></description><pubDate>Fri, 05 Jun 2026 12:56:17 GMT</pubDate></item><item><title>Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress</title><link>https://news.cision.com/h--lundbeck-a-s/r/lundbeck-presents-positive-phase-iib-data-for-bocunebart--lu-ag09222--anti-pacap-mab--in-migraine-pr,c4357979</link><guid isPermaLink="false">cision5378011</guid><description><![CDATA[· The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly migraine days versus placebo over Weeks 1–12 in patients with one to four prior preventive treatment failures
  · Bocunebart was generally well tolerated, with no new safety signals identified
  · The totality of the presented clinical data from the bocunebart Phase I-IIb program strengthens the evidence for PACAP pathway inhibition as a novel therapeutic approach for people severely impacted by migraine]]></description><pubDate>Thu, 04 Jun 2026 20:00:00 GMT</pubDate></item><item><title>Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics</title><link>https://news.cision.com/photocure/r/photocure-asa-to-acquire-vesica-health-inc--strengthening-leadership-in-bladder-cancer-diagnostics,c4358110</link><guid isPermaLink="false">cision5377938</guid><description><![CDATA[Oslo, Norway – June 4, 2026 – Photocure ASA (OSE: PHO), a leader in bladder cancer diagnostics, today announced the signing and successful completion of its acquisition of Vesica Health, a U.S. established precision diagnostics company advancing AssureMDx, a urine-based molecular test for the early detection of bladder cancer, in a transaction designed to expand Photocure’s position across the bladder cancer care continuum.
Transaction Highlights

  ·  USD 30.5M in total cash + stock transaction
    · Of which USD 3.0M equity investment made during Q1 2026.
      · Net consideration of]]></description><pubDate>Thu, 04 Jun 2026 14:30:00 GMT</pubDate></item><item><title>DexTech Medical's myeloma study fully recruited, preliminary results very positive</title><link>https://news.cision.com/dextech/r/dextech-medical-s-myeloma-study-fully-recruited--preliminary-results-very-positive,c4357397</link><guid isPermaLink="false">cision5377378</guid><description><![CDATA[The study was conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment has lasted for a total of 14 weeks with 2 doses per month. Three dose levels of OsteoDex (ODX) have been studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Uddevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital]]></description><pubDate>Thu, 04 Jun 2026 06:00:00 GMT</pubDate></item><item><title>Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments</title><link>https://news.cision.com/h--lundbeck-a-s/r/lundbeck-partners-with-cradle-to-discover-and-optimize-brain-disorder-treatments,c4357042</link><guid isPermaLink="false">cision5376484</guid><description><![CDATA[Collaboration’s initial focus will focus on two antibody programs targeting CNS diseases
VALBY, Denmark & AMSTERDAM, 03 June 2026 – H. Lundbeck A/S (Lundbeck), a global biopharmaceutical company focused exclusively on brain health, and Cradle, a leading AI platform for protein engineering, today announced a partnership to help Lundbeck discover and optimize biotherapeutics that ultimately can improve patient outcomes.

It is estimated that more than half of the world’s population is impacted by brain disorders, and the effects are felt throughout society. Speeding up innovation time to]]></description><pubDate>Wed, 03 Jun 2026 12:00:00 GMT</pubDate></item><item><title>CuraCell Publishes Third and Final Clinical Report from CytoPLY™ Named-Patient Program, Demonstrating Tumour Responses Across Multiple Difficult-to-Treat Solid Tumours</title><link>https://news.cision.com/curacell-tx-ab/r/curacell-publishes-third-and-final-clinical-report-from-cytoply--named-patient-program--demonstratin,c4356707</link><guid isPermaLink="false">cision5375830</guid><description><![CDATA[Stockholm, Sweden - CuraCell TX AB (CuraCell) today announced the publication in Cytotherapy of the third and final scientific report emerging from its CytoPLY™ named-patient treatment program. The latest publication, “Targeting Intratumoral Heterogeneity in Pancreatic Cancer with Sequential TIL Infusions” adds pancreatic ductal adenocarcinoma (PDAC) to a growing body of clinical evidence supporting the potential of personalized tumour-infiltrating lymphocyte (TIL) therapy in heavily pretreated solid tumours.

Together, the three publications summarize clinical observations from named-]]></description><pubDate>Wed, 03 Jun 2026 05:00:00 GMT</pubDate></item><item><title>Camurus announces expansion of Lilly collaboration</title><link>https://news.cision.com/camurus-ab/r/camurus-announces-expansion-of-lilly-collaboration,c4356354</link><guid isPermaLink="false">cision5374715</guid><description><![CDATA[Lund, Sweden — 1 June 2026 — Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company (“Lilly”) has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly’s exclusive, global rights to Camurus’ FluidCrystal[®] technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.

The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual GLP-1 and GIP receptor agonists, triple]]></description><pubDate>Mon, 01 Jun 2026 15:00:00 GMT</pubDate></item><item><title>Admission of Further Securities to Trading</title><link>https://news.cision.com/astrazeneca/r/admission-of-further-securities-to-trading,c4355941</link><guid isPermaLink="false">cision5374658</guid><description><![CDATA[1 June 2026

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1   Details of the issuer
a)  Name                        AstraZeneca PLC
b)  LEI                         PY6ZZQWO2IZFZC3IOL08
2   Details of the transferable
    securities admitted to
    trading
a)  Name, type and              Ordinary Shares of $0.25
    identification code         eachISIN: GB0009895292
b)  Regulated market            London Stock]]></description><pubDate>Mon, 01 Jun 2026 14:05:00 GMT</pubDate></item><item><title>Total Voting Rights</title><link>https://news.cision.com/astrazeneca/r/total-voting-rights,c4355955</link><guid isPermaLink="false">cision5374649</guid><description><![CDATA[1 June 2026

Total Voting Rights

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 May 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,009,750 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,009,750.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify]]></description><pubDate>Mon, 01 Jun 2026 14:00:00 GMT</pubDate></item><item><title>Sobi to present new data on pegcetacoplan at ERA 2026</title><link>https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-to-present-new-data-on-pegcetacoplan-at-era-2026,c4355711</link><guid isPermaLink="false">cision5374266</guid><description><![CDATA[Sobi® today announced that new data from the pegcetacoplan clinical development programme and related research in C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) will be presented at the 63rd Congress of the European Renal Association (ERA), taking place from 3 - 6 June 2026 in Glasgow, UK. Presentations will be made in collaboration with Apellis Pharmaceuticals (now part of Biogen).

 

The presentations include new analyses from the pivotal Phase 3 VALIANT study and its long-term extension VALE study evaluating pegcetacoplan in]]></description><pubDate>Mon, 01 Jun 2026 08:00:00 GMT</pubDate></item><item><title>Number of shares and votes in BioArctic AB (publ) as of May 29, 2026</title><link>https://news.cision.com/bioarctic/r/number-of-shares-and-votes-in-bioarctic-ab--publ--as-of-may-29--2026,c4355174</link><guid isPermaLink="false">cision5373704</guid><description><![CDATA[Stockholm, May 29, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 5,000 stock options of series 2019/2028.
As of May 29, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,724,485 shares, of which 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten]]></description><pubDate>Fri, 29 May 2026 16:30:00 GMT</pubDate></item><item><title>Klaria Interim Report Q1 2026</title><link>https://news.cision.com/klaria-pharma-holding-ab/r/klaria-interim-report-q1-2026,c4355227</link><guid isPermaLink="false">cision5373428</guid><description><![CDATA[Klaria Interim Report Q1 2026 1 January - 31 March
Summary of the interim report

First quarter of 2026 The group in total

- Net sales 0.1 MSEK (9.0 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 4.9 MSEK (3.4 MSEK)

- Profit after tax amounted to -8.7 MSEK (-1.6 MSEK)

- Earnings per share for the quarter amounted to -0.04 SEK (-0.01 SEK)

- Cash flow from operating activities amounted to -0.1 MSEK (0.9 MSEK)

- Liquid assets on the balance sheet date amounted to 0.3 MSEK (1.5 MSEK)

- Group equity as of March 31 amounted to -20.6]]></description><pubDate>Fri, 29 May 2026 11:28:11 GMT</pubDate></item><item><title>Imfinzi approved in US for early bladder cancer</title><link>https://news.cision.com/astrazeneca/r/imfinzi-approved-in-us-for-early-bladder-cancer,c4354945</link><guid isPermaLink="false">cision5373021</guid><description><![CDATA[29 May 2026

 

Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

 

Based on POTOMAC Phase III trial results which showed a 32% reduction in the risk of high-risk disease recurrence, progression or death after one year of Imfinzi added to BCG vs. BCG alone

                                           

AstraZeneca's Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients]]></description><pubDate>Fri, 29 May 2026 06:00:00 GMT</pubDate></item><item><title>Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2026/2029</title><link>https://news.cision.com/camurus-ab/r/camurus--board-of-directors-exercises-authorization-for-repurchase-of-shares-for-the-purpose-of-secu,c4354892</link><guid isPermaLink="false">cision5372904</guid><description><![CDATA[Lund, Sweden — 28 May 2026 — The Annual General Meeting of Camurus on 28 May 2026, resolved – for the purpose of ensuring that the company can fulfill its commitments under the long-term incentive program for employees of the Camurus group resolved by the Annual General Meeting (Performance Share Plan 2026/2029) – on a directed share issue of no more than 570,000 redeemable and convertible series C shares. DNB Carnegie Investment Bank AB has subscribed for all 570,000 series C shares. The subscription price amounted to SEK 0.025 per share, which corresponds to the quota value of the shares.]]></description><pubDate>Thu, 28 May 2026 18:30:00 GMT</pubDate></item><item><title>Resolutions at the annual general meeting 2026 in Camurus</title><link>https://news.cision.com/camurus-ab/r/resolutions-at-the-annual-general-meeting-2026-in-camurus,c4354881</link><guid isPermaLink="false">cision5372883</guid><description><![CDATA[Lund, Sweden — 28 May 2026 — Camurus AB’s (CAMX) annual general meeting 2026 was held today, Thursday 28 May, at The Loop in Lund.

The annual general meeting adopted the presented income statements and balance sheets as well as the remuneration report prepared by the Board and granted discharge of liability to Board members and the CEO. In addition, the following main resolutions were passed.

Election of Board members and auditor
Per Olof Wallström, Hege Hellstrøm, Jakob Lindberg, Stefan Persson, Erika Söderberg Johnsson, Fredrik Tiberg, Elisabeth Björk and Robert McQuade were re-]]></description><pubDate>Thu, 28 May 2026 17:00:00 GMT</pubDate></item><item><title>Bulletin from the Annual General Meeting in BioArctic AB (publ)</title><link>https://news.cision.com/bioarctic/r/bulletin-from-the-annual-general-meeting-in-bioarctic-ab--publ-,c4354575</link><guid isPermaLink="false">cision5372871</guid><description><![CDATA[Stockholm, 28 May 2026. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made.
Adoption of the income statement and the balance sheet: allocation of result and determination of the record date for the dividend

The Annual General Meeting adopted the income statement and balance sheet for the company and for the group in accordance with the submitted accounting documents and resolved, in accordance with the board of directors’ proposal, that a dividend of SEK 2 per share shall be paid, with 1 June 2026]]></description><pubDate>Thu, 28 May 2026 16:30:00 GMT</pubDate></item><item><title>Recipharm boosts BFS capacity with strategic manufacturing investment</title><link>https://news.cision.com/recipharm-ab/r/recipharm-boosts-bfs-capacity-with-strategic-manufacturing-investment,c4354536</link><guid isPermaLink="false">cision5372508</guid><description><![CDATA[· New BFS line adds significant sterile manufacturing capacity to support growing customer demand
  · With 50 years of BFS expertise, Recipharm supports ophthalmic and vaccine programmes
  · Integrated BFS capabilities span early feasibility, clinical supply and commercial manufacturing
Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced a multi-million investment in a new Blow-Fill-Seal (BFS) manufacturing line, expanding capacity to support customer programmes from development through commercial supply. The investment builds on 50 years]]></description><pubDate>Thu, 28 May 2026 09:21:13 GMT</pubDate></item><item><title>Klaria adjusts annual report release date</title><link>https://news.cision.com/klaria-pharma-holding-ab/r/klaria-adjusts-annual-report-release-date,c4354374</link><guid isPermaLink="false">cision5372284</guid><description><![CDATA[Klaria Pharma Holding (publ) has announced that the 2025 annual report will be published on May 29th. As the annual general meeting has now been moved to June 26th, the annual report will be released on June 5th.]]></description><pubDate>Thu, 28 May 2026 06:35:14 GMT</pubDate></item><item><title>AcuCort publishes newsletter with CEO update</title><link>https://news.cision.com/acucort-ab/r/acucort-publishes-newsletter-with-ceo-update,c4353526</link><guid isPermaLink="false">cision5370929</guid><description><![CDATA[Pharmaceutical company AcuCort has published its newsletter for May 2026. In the newsletter, the company highlights key milestones, including the launch and sales in the Nordic market, the commercial agreement with Glenmark Pharmaceuticals, and the ongoing work towards a future market approval application in the United States.
The newsletter also includes recorded presentations, including the Q1 presentation.

The newsletter is available here: 
https://bit.ly/4uyczVu

Would you like to receive future newsletters directly in your inbox?

Sign up here:
https://www.acucort.se/EN/media/]]></description><pubDate>Wed, 27 May 2026 06:00:00 GMT</pubDate></item></channel></rss>